Kennedy Calls for a "Regulated Peptide Marketplace": What Is Confirmed So Far?
TL;DR: On 21 Oct 2026 Kennedy called for a regulated US peptide marketplace. No rule is published, and US compounding policy does not alter UK reagent law.
What Did Kennedy Say About a Regulated Peptide Marketplace?
A radio news item dated 21 October 2026 carried the headline that HHS Secretary Robert F. Kennedy Jr. called for a regulated peptide marketplace.[1] Wire coverage summarised the framing: the aim is that buyers receive what the label says, from inspected factories, and that the FDA had sent a proposal to the White House for review the previous Thursday, which matches the 14 October OMB receipt date.[1][6]
We could not retrieve the full text of these reports from our publishing environment, so this guide treats them as reported claims. No policy document has been published, and nothing here is a legal change.
What Is the Dated Timeline Behind the Remarks?
| Date | Event | Status |
|---|---|---|
| 2023 | FDA moved several peptides to its compounding "Category 2", and many pharmacies stopped offering them[3] | Reported |
| February 2026 | Kennedy said on a podcast he expected about 14 injectable peptides to change status within weeks[3] | Statement, not a rule |
| April 2026 | FDA said it would put BPC-157, TB-500 and others to outside advisers[4] | Process step |
| 23–24 July 2026 | Advisory committee recommended six peptide-related bulk substances for the 503A list[5] | Non-binding |
| 14 October 2026 | Draft "Interim Access Policy" (RIN 0910-ZD94) received by OMB[6] | Under review, text unpublished |
| 21 October 2026 | Kennedy reported calling for a regulated marketplace[1] | Headline-level |
Our earlier guides cover individual steps in detail: the July committee vote and the OMB filing.
What Do Critics Say?
Peter Lurie of the Center for Science in the Public Interest was quoted calling the prospect of peptides reaching the market without clinical testing a "profound threat" to the FDA's decades-old system for vetting drugs.[4] Press coverage also notes that BPC-157 and TB-500 are prohibited by international sports authorities.[4] Even if the advisers and FDA agree, the agency must still draft and publish rules, so any change would follow a formal process.
Reading note: a stated policy goal, a draft under review and a published rule are three different things. Only the last changes legal status.
What Remains Unknown?
Scope
Which compounds would be covered, and whether the list mirrors the July committee votes, is unpublished.
Mechanism
Reporting points to enforcement discretion, but no document confirms it.
Quality rules
What "inspected factories" would mean in practice, including testing and labelling standards, has not been defined.
Timing
OMB review has no legal deadline.
Does a US Marketplace Proposal Change UK Research-Reagent Rules?
No. The proposals concern US pharmacy compounding. UK supply of research reagents is governed by separate law and MHRA guidance; see are research peptides legal in the UK?. Keep three categories apart: licensed pharmaceutical development, US regulatory process, and research-use compounds handled in vitro under a supplier's certificate of analysis.
Retatrutide sits in the first category: it is an investigational Eli Lilly candidate, not part of the peptide-compounding reporting, with a US filing planned for Q1 2027. Gray-market labelling problems around it are covered in our counterfeit supply guide, and the research reagent is described on the retatrutide product page. The reagent for BPC-157 is on its product page.
Compounds are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- iHeart (Star 94.1). "RFK Jr. Calls For Regulated Peptide Marketplace", 21 October 2026 (headline-level; full text not retrieved). star941fm.iheart.com
- Glossy. "Health Secretary RFK Jr. teases deregulation of injectable peptides as the category swells and battles counterfeits". glossy.co
- Personal Care Insights. "RFK Jr. pushes to legalize popular injectable peptides amid safety concern backlash". personalcareinsights.com
- Spectrum News. "FDA limits peptides, Robert F. Kennedy Jr., MAHA", 15 April 2026. spectrumlocalnews.com
- Bloomberg Law. "FDA Advisers Back Relaxing Peptide Rules in Win for RFK Jr.", July 2026. news.bloomberglaw.com
- Office of Information and Regulatory Affairs. RIN 0910-ZD94, received 14 October 2026. reginfo.gov
Frequently Asked Questions
What did Kennedy say about peptides on 21 October 2026?
Radio news reporting dated 21 October 2026 carried the headline that HHS Secretary Robert F. Kennedy Jr. called for a regulated peptide marketplace, framed around buyers receiving what the label says from inspected factories. We could not retrieve the full text, so only the headline-level claim is treated as reported.
Is there a regulated US peptide marketplace now?
No. As of 28 October 2026 no policy text has been published. A draft interim access policy (RIN 0910-ZD94) was received by the Office of Management and Budget on 14 October 2026 and is listed as under review.
Does this affect UK research peptide supply?
No. The proposals concern US pharmacy compounding. UK research-reagent supply sits under separate law and MHRA guidance, and Velox Peptides supplies compounds as in vitro research reagents only.
Is retatrutide part of the US peptide proposals?
Not as far as public reporting shows. Retatrutide is an investigational Eli Lilly drug candidate with a US filing planned for Q1 2027; the peptide-policy reporting centres on compounds such as BPC-157 and TB-500.
Why do critics object to easing peptide rules?
Critics quoted in press coverage, including the Center for Science in the Public Interest's Peter Lurie, argue that allowing peptides onto the market without clinical testing undermines the FDA's drug-vetting system.